Guidelines for Bevacizumab Induced Hypertension

Network Guidance Document

<table>
<thead>
<tr>
<th>Status</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expiry Date</td>
<td>November 2015</td>
</tr>
<tr>
<td>Version Number</td>
<td>1</td>
</tr>
<tr>
<td>Publication Date</td>
<td>October 2011 (reviewed November 2013)</td>
</tr>
</tbody>
</table>
Contents

1.0 Overview ......................................................................................................................... 3

2.0 Management of Bevacizumab induced Hypertension .................................................. 3
  2.1 Duration of treatment ....................................................................................................... 4
  2.2 Summary .......................................................................................................................... 5

References ............................................................................................................................... 5

Document Administration ....................................................................................................... 6
  Approval Record ...................................................................................................................... 6
  Enquiries ................................................................................................................................. 6
  Document Location ................................................................................................................ 6
  Revision History ..................................................................................................................... 7
1.0 Overview

Bevacizumab may cause hypertension in patients that are treated with the drug. This is due to the mechanism of action of bevacizumab and its affects on the vascular endothelial growth factor signalling pathway and angiogenesis.

An increased incidence of hypertension (all grades) of up to 34% was observed in bevacizumab-treated patients in clinical trials compared with up to 14% in those treated with comparator. Grade 3 and 4 hypertension (requiring oral anti-hypertensive medicines) in patients receiving bevacizumab ranged from 0.4% to 17.9%. Grade 4 hypertension (hypertensive crisis) occurred in up to 1.0% of patients treated with bevacizumab and chemotherapy compared to up to 0.2% of patients treated with the same chemotherapy alone.

Clinical safety data suggest that the incidence of hypertension is likely to be dose-dependent. Pre-existing hypertension should be adequately controlled before starting treatment with bevacizumab.

2.0 Management of Bevacizumab induced Hypertension

Hypertension is generally adequately controlled with oral anti-hypertensives such as angiotensin-converting enzyme (ACE) inhibitors, diuretics and calcium-channel blockers. However, if patients are to receive a cisplatin containing chemotherapy regime, then the use of diuretics is not recommended for managing hypertension.

Key steps for management:

1. Conduct and document a formal risk assessment for potential cardiovascular complications before treatment with bevacizumab is initiated. This should include standardised blood pressure measurements – at least two separate sessions
2. Recognise that pre-existing hypertension will be common in cancer patients and should be identified and addressed before treatment with bevacizumab is initiated.
3. Actively monitor blood pressure throughout treatment with more frequent assessments during the first cycle.
4. The goal for hypertension control is a maximum blood pressure of 140/90 mmHg. However, if a patient has additional risk factors e.g. diabetic or chronic kidney disease, then the target blood pressure of less than 130/80 mmHg is the current recommendation.
5. Manage blood pressure elevations aggressively to avoid the development of complications associated with excessive/prolonged elevations. Seek advice from Cardiology colleagues if necessary.
6. If medically significant hypertension cannot be controlled with antihypertensive therapy, or if the patient develops hypertensive crisis or hypertensive encephalopathy, bevacizumab should be permanently discontinued.

Taking into account data information from various papers it would appear that the best classes of antihypertensive drugs to treat hypertension caused by bevacizumab would be ACE inhibitors, Angiotensin II inhibitors and calcium channel blockers.

Points to consider when selecting an antihypertensive drug:
<table>
<thead>
<tr>
<th>Class of Drug</th>
<th>Cancer specific cautions or reasons to avoid</th>
<th>Basis for preferred selection</th>
<th>General cautions and contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitors</td>
<td>Co-administration /titration with renal clearance dependent agents (e.g. cisplatin &amp; pemetrexed), hyperkalaemia</td>
<td>Left ventricular systolic dysfunction, diabetic nephropathy</td>
<td>Renovascular disease, peripheral vascular disease, renal impairment</td>
</tr>
<tr>
<td>Angiotensin II inhibitors</td>
<td>Co-administration /titration with renal clearance dependent agents (e.g. cisplatin &amp; pemetrexed), hyperkalaemia</td>
<td>Intolerance of other agents, especially ACE inhibitors, Left ventricular systolic dysfunction, diabetic nephropathy</td>
<td>Renovascular disease, peripheral vascular disease, renal impairment</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>Asthenia, malaise, fatigue, QT interval prolonging drugs</td>
<td>Angina, history of myocardial infarction, anxiety</td>
<td>Bradycardia/heart block, diabetes (risk for hypoglycaemia), asthma/COPD (wheezing), decompensated heart failure</td>
</tr>
<tr>
<td>Calcium channel blockers (e.g. dihydropyridines)</td>
<td>Lower extremity swelling</td>
<td>Elderly patients, isolated systolic hypertension</td>
<td>Pre-existing oedema, slow onset of action</td>
</tr>
<tr>
<td>Thiazide diuretics</td>
<td>Gout, hyperuricaemia, hypokalaemia, young patients (age ≤45yrs), QT interval prolonging drugs</td>
<td>Elderly patients, isolated systolic hypertension, secondary stroke prevention, typically least expensive</td>
<td>Gout, documented sulfa allergy</td>
</tr>
</tbody>
</table>

### 2.1 Duration of treatment

The hypertensive effects of bevacizumab should dissipate when bevacizumab is discontinued. Ensure that blood pressure is monitored closely on discontinuation of treatment and that the doses of any prescribed antihypertensive drugs are monitored and reduced as appropriate.
2.2 Summary

Assess cardiac risk factors prior to initiation of treatment including BP measurements

Actively monitor BP throughout treatment especially during cycle one

Target BP is 140/90 mmHg unless other risk factors (e.g. diabetes) then target BP is 130/80 mmHg

Treat BP elevations aggressively using an appropriate antihypertensive for each patient

If hypertension is not controllable then treatment with bevacizumab may need to be interrupted. Refer patient to Cardiologist for assessment

If a patient develops hypertension that cannot be controlled to consistently < 180/110mmHg, bevacizumab should be withheld and the patient referred to a hypertension specialist.

References


Document Administration

Approval Record

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Name / Title</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Julia Hall</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultant Oncologist &amp; Chair of the Colorectal NOG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair of the Network Chemotherapy Group</td>
<td></td>
</tr>
</tbody>
</table>

Enquiries

All enquiries relating to this document should be addressed to:

**Addressee:**
Name
Address
Telephone:
Email:

**Addressee:**
Name
Address
Telephone:
Email:

**Addressee:**
Name
Address
Telephone:
Email:

Document Location

The document is located in the Kent and Medway Cancer Network office, in hardcopy and electronic format. Also mention here if it can be found on any of the Network websites.

DATE OF NEXT REVIEW

This item is next to be reviewed in November 2015
### Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Version</th>
<th>Status</th>
<th>Author</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 2011</td>
<td>0.1</td>
<td>Draft</td>
<td>K Miller/ Colorectal NOG</td>
<td>New document</td>
</tr>
<tr>
<td>October 2011</td>
<td>1</td>
<td>Final</td>
<td>K Miller/ Colorectal NOG</td>
<td>Published</td>
</tr>
<tr>
<td>November 2013</td>
<td></td>
<td></td>
<td></td>
<td>Reviewed by Colorectal NOG – no changes.</td>
</tr>
</tbody>
</table>
MEASURES Addressed BY THIS EVIDENCE ITEM

This item of evidence is submitted against the following measures:
ORIGINATORS OF THIS EVIDENCE ITEM

K Miller / Colorectal NOG